DYNE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.73 USD | +4.37% |
|
+3.65% | +85.94% |
| 03-25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
| 03-25 | Dyne Therapeutics, Inc. Announces Management Changes | CI |
Chart calendar Dyne Therapeutics, Inc.
96b74b4c1c.6WrerTDlLurkUat4SmwRlpJzx1yrvEkVxxnmJdwEseI.swC8-1GBTY-wYuc3ZwV21N5LsRrZ-iEkljSMSZ1F85OcD4HhAbBamKsm7g~dc0bc49b03469c5cd0170ba8128a0928
Upcoming events on Dyne Therapeutics, Inc.
Past events on Dyne Therapeutics, Inc.
| 02/04/2024 14:50 | Cantor Fitzgerald Muscular Dystrophy Symposium - Fireside Chat |
| 20/03/2024 12:30 | Stifel CNS Day |
| 06/03/2024 16:30 | Muscular Dystrophy Association Clinical & Scientific Conference - Kevin Flanigan |
| 06/03/2024 15:15 | Muscular Dystrophy Association Clinical & Scientific Conference - Valeria Sansone |
| 05/03/2024 12:30 | Q4 2023 Earnings Release |
| 14/02/2024 19:40 | Oppenheimer Healthcare Life Sciences Conference |
| 08/02/2024 16:00 | Guggenheim Healthcare Talks Biotechnology Conference |
| 09/01/2024 22:15 | JPMorgan Healthcare Conference |
| 03/01/2024 13:00 | Phase 1/2 DELIVER Trial Results Call |
| 28/11/2023 18:30 | Piper Sandler Healthcare Conference |
| 14/11/2023 21:45 | Stifel Healthcare Conference |
| 30/10/2023 11:30 | Q3 2023 Earnings Release |
| 12/10/2023 14:30 | Jefferies Inaugural Biotech CNS/Neuro Summit |
| 03/10/2023 16:00 | Chardan Genetic Medicines Conference |
| 11/09/2023 21:15 | Morgan Stanley Global Healthcare Conference |
| 03/08/2023 12:30 | Q2 2023 Earnings Release |
| 08/06/2023 19:00 | Jefferies Global Healthcare Conference |
| 24/05/2023 14:00 | Annual General Meeting |
| 18/05/2023 00:00 | American Society of Gene & Cell Therapy Meeting - Abstract Number : 82 |
| 15/05/2023 | American Society of Gene Cell Therapy Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -57,9 -46,8 -23.92% | -149 -142 -4.64% | -169 -165 -2.6% | -240 -228 -5.29% | -224 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -58,6 -47,4 -23.78% | -150 -148 -1.67% | -171 -176 2.94% | -242 -233 -3.95% | -282 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -59,4 -47,9 -24.02% | -149 -145 -2.76% | -168 -176 4.53% | -236 -226 -4.34% | -273 |
|
Net income Million USD | Released Forecast Spread | -14,9 | -59,4 -48,0 -23.9% | -149 -147 -1.64% | -168 -174 3.59% | -236 -227 -3.97% | -274 |
|
EPS USD | Released Forecast Spread | -1,83 | -4,13 -2,25 -83.46% | -2,93 -2,91 -0.75% | -3,23 -3,35 3.66% | -3,95 -3,78 -4.37% | -3,25 |
| Announcement Date | 25/08/20 | 04/03/21 | 10/03/22 | 02/03/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -51,6 -45,0 -14.71% | -35,4 -40,0 11.61% | -52,3 -36,0 -45.26% | -41,9 -48,0 12.75% | -39,7 -35,0 -13.56% | -45,1 -39,0 -15.52% | -66,3 -41,0 -61.72% | -61,8 -36,0 -71.78% | -67,3 -56,0 -20.16% | |||||
|
EBIT Million USD | Released Forecast Spread | -52,0 -49,5 -5.02% | -35,8 -45,5 21.36% | -52,8 -41,1 -28.32% | -42,3 -49,1 13.94% | -40,1 -45,3 11.3% | -45,5 -42,6 -6.83% | -66,7 -47,6 -40.24% | -62,3 -53,9 -15.51% | -67,7 -58,5 -15.78% | -67,1 | -68,8 | -71,1 | -72,9 | -87,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -51,8 -47,9 -8.01% | -35,6 -45,4 21.67% | -52,3 -40,9 -27.81% | -41,4 -48,7 15.09% | -38,8 -46,4 16.31% | -44,2 -42,7 -3.53% | -64,9 -47,0 -38.08% | -60,2 -52,6 -14.38% | -66,6 -56,9 -17.07% | -64,4 | -65,8 | -67,5 | -70,4 | -85,0 |
|
Net income Million USD | Released Forecast Spread | -51,8 -49,4 -4.77% | -35,6 -45,4 21.67% | -52,3 -40,9 -27.81% | -41,4 -49,0 15.52% | -38,8 -44,8 13.27% | -44,2 -42,0 -5.18% | -64,9 -47,0 -38.19% | -60,2 -53,2 -13.11% | -66,6 -57,8 -15.32% | -65,3 | -66,4 | -68,6 | -70,7 | -85,0 |
|
EPS USD | Released Forecast Spread | -1,00 -0,99 -1.11% | -0,69 -0,88 21.88% | -1,01 -0,79 -27.44% | -0,80 -0,92 13.14% | -0,74 -0,85 12.8% | -0,78 -0,77 -1.46% | -1,08 -0,81 -33.76% | -0,99 -0,83 -18.83% | -1,09 -0,92 -18.87% | -0,80 | -0,81 | -0,83 | -0,83 | -1,02 |
| Announcement Date | 10/03/22 | 02/05/22 | 04/08/22 | 03/11/22 | 02/03/23 | 11/05/23 | 03/08/23 | 30/10/23 | 05/03/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Dyne Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- DYN Stock
- Calendar Dyne Therapeutics, Inc.
